Classic examples include gefitinib inhibition of EGFR mutant kinase in non-small cell lung cancer (NSCLC) and imatinib inhibition of BCR-ABL fusion kinase in chronic myeloid leukemia [4, 5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.